Pereira M, Galvani R, Goncalves-Silva T, de Vasconcelo Z, Bonomo A
Front Immunol. 2024; 15:1379376.
PMID: 38690280
PMC: 11058666.
DOI: 10.3389/fimmu.2024.1379376.
Huang Y, Zou Y, Jiao Y, Shi P, Nie X, Huang W
Front Immunol. 2022; 13:751296.
PMID: 35296079
PMC: 8920494.
DOI: 10.3389/fimmu.2022.751296.
Zhang Y, Guo C, Sun C, Chen Y, Zhu H, Xi J
Mol Clin Oncol. 2020; 12(6):574-580.
PMID: 32337040
PMC: 7179384.
DOI: 10.3892/mco.2020.2027.
Ali N, Ullah H, Shaikh M, Adil S
Int J Hematol Oncol. 2020; 8(4):IJH21.
PMID: 31903183
PMC: 6939220.
DOI: 10.2217/ijh-2019-0006.
Lee C, Lee S, Haneuse S
Stat Methods Med Res. 2019; 29(6):1573-1591.
PMID: 31436136
PMC: 8096611.
DOI: 10.1177/0962280219869364.
T Regulatory Cells in Donor Grafts May Predict the Severity of Acute Graft Versus Host Disease After Matched Sibling Donor Allogenic Peripheral Blood Stem Cell Transplantation.
Chandra D, Singh J, Deka R, Ahuja A, Sharma R, Mishra P
Indian J Hematol Blood Transfus. 2019; 35(2):233-239.
PMID: 30988557
PMC: 6439099.
DOI: 10.1007/s12288-018-01071-9.
Predictive Role of Circulating Immune Cell Subtypes Early after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia.
Kim T, Park S, Lim J, Min G, Park S, Jeon Y
Int J Stem Cells. 2019; 12(1):73-83.
PMID: 30595008
PMC: 6457701.
DOI: 10.15283/ijsc18094.
Prediction of absolute risk of acute graft-versus-host disease following hematopoietic cell transplantation.
Lee C, Haneuse S, Wang H, Rose S, Spellman S, Verneris M
PLoS One. 2018; 13(1):e0190610.
PMID: 29346409
PMC: 5773230.
DOI: 10.1371/journal.pone.0190610.
Ex Vivo CD34-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host....
Barba P, Hilden P, Devlin S, Maloy M, Dierov D, Nieves J
Biol Blood Marrow Transplant. 2016; 23(3):452-458.
PMID: 28017734
PMC: 5398850.
DOI: 10.1016/j.bbmt.2016.12.633.
Advances in predicting acute GVHD.
Harris A, Ferrara J, Levine J
Br J Haematol. 2012; 160(3):288-302.
PMID: 23205489
PMC: 3552019.
DOI: 10.1111/bjh.12142.
Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
Chaidos A, Patterson S, Szydlo R, Chaudhry M, Dazzi F, Kanfer E
Blood. 2012; 119(21):5030-6.
PMID: 22371885
PMC: 6143158.
DOI: 10.1182/blood-2011-11-389304.
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.
Doubrovina E, Oflaz-Sozmen B, Prockop S, Kernan N, Abramson S, Teruya-Feldstein J
Blood. 2011; 119(11):2644-56.
PMID: 22138512
PMC: 3311278.
DOI: 10.1182/blood-2011-08-371971.
Storage of hemopoietic stem cells.
Pamphilon D, Mijovic A
Asian J Transfus Sci. 2011; 1(2):71-6.
PMID: 21938237
PMC: 3168124.
DOI: 10.4103/0973-6247.33848.
High frequencies of CD62L⁺ naive regulatory T cells in allografts are associated with a low risk of acute graft-versus-host disease following unmanipulated allogeneic haematopoietic stem cell transplantation.
Lu S, Liu K, Liu D, Xu L, Huang X
Clin Exp Immunol. 2011; 165(2):264-77.
PMID: 21635226
PMC: 3142651.
DOI: 10.1111/j.1365-2249.2011.04418.x.
Prevention of GVHD without losing GVL effect: windows of opportunity.
Zhang P, Chen B, Chao N
Immunol Res. 2010; 49(1-3):49-55.
PMID: 21136200
DOI: 10.1007/s12026-010-8193-7.
Long-term results after transplantation of CD34+ selected (CellPro) versus unselected peripheral blood progenitor cells (PBPC) from related allogeneic donors.
Kopp H, Wirths S, Faul C, Bethge W, Scheding S, Brugger W
J Cancer Res Clin Oncol. 2010; 136(12):1921-7.
PMID: 20217128
DOI: 10.1007/s00432-010-0851-6.
High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT.
Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani B, Zeilah J
Blood. 2006; 108(4):1291-7.
PMID: 16627754
PMC: 1895877.
DOI: 10.1182/blood-2006-02-003996.
The thrombopoietin receptor, c-Mpl, is a selective surface marker for human hematopoietic stem cells.
Ninos J, Jefferies L, Cogle C, Kerr W
J Transl Med. 2006; 4:9.
PMID: 16480521
PMC: 1402332.
DOI: 10.1186/1479-5876-4-9.
Allogeneic T cells induce rapid CD34+ cell differentiation into CD11c+CD86+ cells with direct and indirect antigen-presenting function.
Abbasian J, Mahmud D, Mahmud N, Chunduri S, Araki H, Reddy P
Blood. 2006; 108(1):203-8.
PMID: 16478883
PMC: 1895833.
DOI: 10.1182/blood-2005-11-4330.